In this article:

Heron Therapeutics (HRTX) Gets a Buy Rating from Needham

In this article:
In this article:

In a report released today, Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics (HRTXResearch Report), with a price target of $24.00. The company’s shares closed last Thursday at $9.55, close to its 52-week low of $8.29.

According to TipRanks.com, Belanger is a 2-star analyst with an average return of 1.0% and a 39.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Heron Therapeutics with a $42.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $22.40 and a one-year low of $8.29. Currently, Heron Therapeutics has an average volume of 1.69M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.

Read More on HRTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed